secwatch.observer — SEC 8-K summary
======================================

Issuer:     SOLIGENIX, INC. (SNGX)
CIK:        0000812796
Form:       8-K
Filed at:   2023-05-01T23:59:59+00:00
Accession:  0001558370-23-007396
Event type: m_and_a
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Soligenix obtains exclusive option for Phase 2/3-ready topical Pentoxifylline in Behçet's Disease
--------------------------------------------------------------------------------

- Exclusive option agreement with Silk Road Therapeutics to acquire topical Pentoxifylline for mucocutaneous ulcers in Behçet's Disease.
- BD affects ~18,000 US, 80,000 EU patients; orphan disease with no cure, current treatments limited.
- Phase 2 trial showed 83% of PTX patients had ulcer shrinkage by Day 2 vs 19% colchicine (p<0.0001).
- By Day 4, 72% on PTX had undetectable ulcer vs 29% colchicine; no serious adverse events.
- Program is Phase 2/3-ready; Soligenix plans FDA discussions on trial design.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/812796/000155837023007396/0001558370-23-007396-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/812796/000155837023007396/sngx-20230501x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-007396

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer